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1Abstract
Background
Breathlessness remains a common and distressing symptom in people with advanced disease with
few effective treatment options. Repurposing of existing medicines has been effective in other areas
of palliative care, for example antidepressants to treat pain, and offers an opportunity to deliver
improved symptom control in a timely manner. Previous case series have shown reduced
breathlessness following the use of sertraline (a selective serotonin reuptake inhibitor) in people
with chronic obstructive pulmonary disease.
Cases
Six cases where mirtazapine, a noradrenergic and specific serotonergic antidepressant, was used to
treat chronic breathlessness in advanced lung disease.
Case management
All cases received mirtazapine at a starting dose of 15mg, prescribed under the care of their primary
care physician.
Case outcome
All cases reported less breathlessness and being able to do more. Some cases also reported
beneficial effects on anxiety, panic, appetite and sleep. Cases had been receiving mirtazapine for a
variable time period (2 weeks to 5 months) at the time of the interviews. No adverse effects were
reported.
Discussion
Patients with chronic breathlessness in this case series reported benefits during mirtazapine
treatment. To determine the effectiveness of mirtazapine in alleviating breathlessness and
improving quality of life in chronic lung disease, blinded randomised trials are warranted.
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2Key Statements
What is already known about the topic?
 Breathlessness is a common and distressing symptom in advanced disease, with few
effective treatment options
 New treatments are urgently needed
 Repurposing of existing medicines has been effective in other areas of palliative care and
offers a potential opportunity to deliver improved symptom control in a timely manner
What this paper adds
 This case series is the first to report the use of mirtazapine in the management of chronic
breathlessness
 Patients with advanced lung disease and chronic breathlessness reported mirtazapine to be
of benefit to them
 Patients reported less breathlessness and being able to do more, as well as beneficial effects
on anxiety, panic, appetite, and sleep
Implications for practice, theory or policy
 In this case series beneficial effects were reported when patients with chronic lung disease
and severe breathlessness were treated with mirtazapine
 However, to determine the effectiveness of mirtazapine in alleviating breathlessness and
improving quality of life in patients with chronic lung disease, blinded randomised trials are
warranted
 Choice of outcome measures which incorporate not only breathlessness, but anxiety, panic,
appetite and sleep will be important when conducting a trial
3Background
Breathlessness is a common and distressing symptom in people with advanced malignant and non-
malignant disease1. Chronic breathlessness has recently been defined as breathlessness at rest or on
minimal exertion that persists despite optimal treatment of the underlying disease2.
Whilst the current evidence-base for individual non-pharmacological interventions is variable, a
multidisciplinary approach combining a number of components (pacing, breathing training and use
of a hand-held fan) has been shown to be effective at improving confidence and control over
breathing3. There are few effective pharmacological treatment options, with some evidence to
support use of opioids, but concerns regarding side effects and small effect sizes, and no evidence
for benzodiazepines4. New treatments are urgently needed. Repurposing existing medicines has
been effective in other areas of palliative care (for example antidepressants to treat pain) and offers
a potential opportunity to deliver improved symptom control in a timely manner.
Two case series of sertraline, a selective serotonin reuptake inhibitor (SSRI), showed a subjective
decrease in breathlessness in patients with chronic obstructive pulmonary disease (COPD) 5 6, and a
phase III trial is ongoing to determine effectiveness to alleviate chronic breathlessness in advanced
illness7. SSRI’s inhibit serotonin re-uptake resulting in a rise in serotonin (5HT) which is thought to
create their therapeutic effect in depression8. The mechanism of action of SSRI’S in breathlessness is
not understood. Serotonin may partially modulate respiratory function, and impact on areas of the
brain relating to fear and anxiety, which appear to be more active during experimentally induced
breathlessness8.
Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA), and enhances 5-
HT1 receptor mediated neurotransmission resulting in increased levels of serotonin in the cortex8.
Increased serotonin may be beneficial in the treatment of chronic breathlessness by inhibiting ‘fear
circuits’ which have been shown to originate in the amygdala, and appear to be more active during
experimentally induced breathlessness8. Respiratory modulation is another possible mechanism as
described above. Mirtazapine is an effective treatment for depression, with a faster onset of action
when compared to SSRI’s. A number of small randomised controlled trials have evaluated efficacy in
anxiety disorders, with some evidence in the treatment of panic disorder9. These effects may be of
additional benefit in breathlessness in chronic lung disease which has been associated with high
levels of anxiety. Mirtazapine blocks 5-HT2 and 5-HT3 receptors, which can be an advantage in
clinical practice by reducing the gastrointestinal effects commonly reported with SSRI’s8. At lower
doses mirtazapine can be quite sedating due to its high affinity for histamine H1 receptors; but at
higher does the increased noradrenergic transmission counteracts this effect8. The most common
4side effects of mirtazapine are increased appetite, weight gain and somnolence, which may be
advantageous to patients with advanced disease who frequently report poor appetite and disrupted
sleep1.
Case presentation
We present a case series of 6 people who received mirtazapine for breathlessness at a starting dose
of 15mg, prescribed under the care of their primary care physician. All had recently participated in a
randomised controlled feasibility trial of mirtazapine for chronic breathlessness, and had requested
continued compassionate use. Qualitative interviews were conducted as part of the feasibility trial.
Data was collected between March 2017 and February 2018. The study received ethical approval
through the London Central Research Ethics Committee (REC reference 16/LO/0091). All patients
entered the trial voluntarily and provided written consent for their anonymised data to be shared in
scientific publications. The trial enrolled people with advanced disease and severe breathlessness, as
indicated by a score of 3 or 4 on the Modified Medical Research Council Dyspnea Scale (mMRC), i.e.
breathlessness after walking 100 yards or after a few minutes on level ground, or when dressing. At
the time of the interviews, patients had been receiving mirtazapine for a variable time period of 2
weeks to 5 months. All patients reported an improvement in breathlessness. This was often
accompanied by a reduction in anxiety, fewer episodes of panic, as well as improvements in appetite
and sleep. Clinical characteristics and reported change in symptoms for all cases are shown in Table
1. Two cases are then described in detail.
5Table 1: Clinical Characteristics and reported change in symptoms
Case
Number
Age Sex Diagnosis mMRC
Dyspnea
Scale
Australia-modified
Karnofsky
Performance scale
HADs Breathlessnes
s
Anxiety/
panic
Appetite Sleep
Case 1 72 Male Interstitial Lung
Disease (ILD)
4 60 7 + + +
Case 2 68 Male Chronic Obstructive
Pulmonary Disease
4 60 27 +++ +++ ++ ++
Case 3 70 Female Interstitial Lung
Disease
3 80 8 + +
Case 4 64 Male Chronic Obstructive
Pulmonary Disease
+++ +++
Case 5 74 Female Chronic Obstructive
Pulmonary Disease
++ ++ + +
Case 6 81 Male Chronic Obstructive
Pulmonary Disease
+ + +
6Case 1:
Case 1 is a 72 year old male who lives at home with his wife. He was diagnosed with interstitial lung
disease 4 years ago, and has a past medical history of bronchiectasis, congestive heart failure and a
permanent pacemaker. Prescribed medications at the time of interview included low dose modified
release morphine prescribed for chronic breathlessness (5mg twice daily), spironolactone and
furosemide. Renal function and liver function tests were within normal limits. His FEV1/FVC ratio
was 1.01. Case 1 described experiencing breathlessness on minimal exertion, and whilst speaking in
conversation. He found he often had to stop when he became breathless to recover. At baseline
Case 1 scored 4 on the mMRC Dyspnea Scale and 60 on the Australia-Modified Karnofsky
Performance Scale (AKPS). His ‘at worst’ breathlessness score on the numerical rating scale was 8,
and he scored 7 on the Hospital Anxiety and Depression Scale (HADs). Case 1 was prescribed
mirtazapine and was reviewed 2 weeks later. He reported improved breathing and being able to do
more including walking further. He described feeling more in control and being able to recover from
episodes of breathlessness more quickly. He also noticed an improvement in his appetite. He did not
report any adverse effects.
Case 2:
Case 2 is a 68 year old male who lives alone. He was diagnosed with severe COPD with emphysema 2
years ago, and is a current smoker. He has a past medical history of hypercapnic respiratory failure
for which he uses home non-invasive ventilation, chronic heart failure and benign asbestos plaques.
Prescribed medications at the time of assessment included Seretide, Salbutamol, Tiotropium,
Spironolactone and Furosemide. Renal function and liver function tests were within normal limits.
His FEV1/FVC ratio was 0.35. Case 2 reported severe breathlessness with episodes of panic causing
him to regularly attend his local Accident & Emergency department. He described feeling frightened
to get out of bed in the morning for fear of triggering breathlessness, and said he didn’t often leave
the house. At baseline he scored 4 on the mMRC Dyspnea Scale and 60 on the Australia-Modified
Karnofsky Performance Scale (AKPS). His ‘at worst’ breathlessness score on the numerical rating
scale was 8, and he scored 27 on the Hospital Anxiety and Depression Scale. Case 2 was prescribed
mirtazapine and was reviewed 5 months later. He described feeling less breathless and being able to
walk further. He also described sleeping better which he felt impacted positively on his breathing.
Case 2 reported no presentations to hospital with breathlessness. He reported no adverse effects
but an increased appetite.
7Discussion/ Conclusion
This case series is the first to report the use of mirtazapine in the management of chronic
breathlessness. Patients with advanced lung disease (COPD and ILD) and chronic breathlessness
report mirtazapine to be of benefit to them.
All patients reported an improvement in breathlessness. This was often accompanied by a reduction
in anxiety, fewer episodes of panic, as well as improvements in appetite and sleep (as shown in
Table 1). No adverse effects were reported despite patients taking mirtazapine for up to 5 months.
Given the safety concerns associated with long-term use of other pharmacological treatments in
breathlessness such as opioids, data on mirtazapine use for up to 5 months is helpful and
contributes towards ongoing pharmacovigilance.
To determine the effectiveness of mirtazapine in alleviating breathlessness and improving quality of
life in chronic lung disease, blinded randomised trials are warranted. On the basis of this case series,
it looks as if ‘improved breathing’ and ‘being able to do more’ are important outcomes. Sleep,
appetite, feeling less frightened and being more in control may also be important. Future work
should aim to unpick how these domains relate and provide a better understanding of the
mechanism of effect of mirtazapine in chronic breathlessness.
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